TP53 status and impact on AML prognosis within the ELN 2022 risk classification.

This study reports 1) frequency of TP53 co-mutation within each component of the ELN 2022 AML risk classification, 2) relevance of TP53 mut VAF<10%, 3) prognostic impact of -7, -5/del(5q), -17/abn(17p), CK/MK or myelodysplasia related gene mutations with/without mutated TP53.